- Home
- NAT vs MNKD Comparison
NAT vs MNKD Comparison
Compare NAT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAT | MNKD |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1997 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NAT | MNKD |
|---|---|---|
| Price | $8.08 | $3.57 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.00 | ★ $8.69 |
| AVG Volume (30 Days) | ★ 4.1M | 3.0M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $77.72 | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | $525.49 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $3.06 | $2.23 |
| 52 Week High | $7.50 | $6.51 |
Technical Indicators
Market Signals| Indicator | NAT | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 73.73 | 35.94 |
| Support Level | $5.42 | $3.30 |
| Resistance Level | N/A | $4.23 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 96.00 | 3.03 |
Price Performance
Historical ComparisonAbout NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.